Skip to main content
. 2016 Sep 6;7(45):73448–73461. doi: 10.18632/oncotarget.11866

Figure 1. Differential sensitivity of human AML cell lines to salinomycin.

Figure 1

A. Bar graphs showing decreased viability in AML cell lines over time following salinomycin treatment at the indicated dosage compared to 0.01% DMSO vehicle control. B. Bar graphs showing altered cell cycle (Propidium Iodide staining) in AML cell lines over time following salinomycin treatment at the indicated dosage or 0.01% DMSO vehicle control. C. Representative morphology images of AML cell lines treated for 48 hours with salinomycin at the indicated dosages or 0.01% DMSO. Mean values ± S.E.M. of biological replicates (n=3) are plotted throughout. ***P < 0.001, **P < 0.01, *P < 0.05, t-test. Scale bar = 4 μm.